Wired reported on Wednesday that OpenAI met with officials of the U.S. Food and Drug Administration to discuss the agency’s use AI to speed up drug reviews.
The report states that OpenAI and FDA have discussed a cderGPT project, which appears to be an AI tool for Center for Drug Evaluation. The CDE regulates prescription and over-the counter drugs in the U.S. According to reports, associates from Elon Musk’s DOGE were also involved in the talks.
It is not uncommon for the drug development process to take over a decade. Wired reports that OpenAI’s collaboration with the FDA is aimed at accelerating a small portion, towards the end, of this timeline. AI has been hailed as a potential accelerator that could be used to speed up some notoriously slow drug development steps. There are still unanswered issues regarding the unreliability AI models.
